Quantitative analysis of neutralizing immune responses to human parvovirus B19 using a novel reverse transcriptase-polymerase chain reaction-based assay

Infection with human parvovirus B19 causes fifth disease, acute and chronic red cell aplasia, fetal hydrops, arthropathy, and other disorders. Antiviral antibodies limit B19 infection in vivo; however, the identification of serologic markers of protection has been hampered by the lack of a quantitat...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infectious diseases Vol. 179; no. 3; p. 619
Main Authors: Bostic, J R, Brown, K E, Young, N S, Koenig, S
Format: Journal Article
Language:English
Published: United States 01.03.1999
Subjects:
Animals
Antibodies, Viral - blood
Antibody Formation
Capsid - immunology
Capsid Proteins
Cell Line
Erythema Infectiosum - immunology
Guinea Pigs
Humans
Immunoglobulin G - blood
Macaca mulatta
Mice
Mice, Inbred BALB C
Neutralization Tests
Parvoviridae Infections - immunology
Parvovirus B19, Human - immunology
Reference Values
Reverse Transcriptase Polymerase Chain Reaction - methods
Viral Vaccines
ISSN:0022-1899
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Infection with human parvovirus B19 causes fifth disease, acute and chronic red cell aplasia, fetal hydrops, arthropathy, and other disorders. Antiviral antibodies limit B19 infection in vivo; however, the identification of serologic markers of protection has been hampered by the lack of a quantitative assay for parvovirus neutralization. A novel in vitro test for parvovirus neutralization has been developed using reverse transcriptase-polymerase chain reaction to detect viral transcripts in a B19-permissive cell line. Parvovirus neutralizing activity was measured in sera from naturally infected individuals, and common features of sera with high neutralizing capacity were identified as protection correlates. Sera that suppressed B19 replication in vitro demonstrated IgG reactivity with capsid proteins VP1 and VP2, but no linear relationship between antibody titer and neutralizing capacity was observed. Sera from experimental animals and human volunteers immunized with a virus-like particle vaccine candidate exhibited B19 neutralizing titers equal to or greater than those observed in natural infections.
AbstractList Infection with human parvovirus B19 causes fifth disease, acute and chronic red cell aplasia, fetal hydrops, arthropathy, and other disorders. Antiviral antibodies limit B19 infection in vivo; however, the identification of serologic markers of protection has been hampered by the lack of a quantitative assay for parvovirus neutralization. A novel in vitro test for parvovirus neutralization has been developed using reverse transcriptase-polymerase chain reaction to detect viral transcripts in a B19-permissive cell line. Parvovirus neutralizing activity was measured in sera from naturally infected individuals, and common features of sera with high neutralizing capacity were identified as protection correlates. Sera that suppressed B19 replication in vitro demonstrated IgG reactivity with capsid proteins VP1 and VP2, but no linear relationship between antibody titer and neutralizing capacity was observed. Sera from experimental animals and human volunteers immunized with a virus-like particle vaccine candidate exhibited B19 neutralizing titers equal to or greater than those observed in natural infections.
Infection with human parvovirus B19 causes fifth disease, acute and chronic red cell aplasia, fetal hydrops, arthropathy, and other disorders. Antiviral antibodies limit B19 infection in vivo; however, the identification of serologic markers of protection has been hampered by the lack of a quantitative assay for parvovirus neutralization. A novel in vitro test for parvovirus neutralization has been developed using reverse transcriptase-polymerase chain reaction to detect viral transcripts in a B19-permissive cell line. Parvovirus neutralizing activity was measured in sera from naturally infected individuals, and common features of sera with high neutralizing capacity were identified as protection correlates. Sera that suppressed B19 replication in vitro demonstrated IgG reactivity with capsid proteins VP1 and VP2, but no linear relationship between antibody titer and neutralizing capacity was observed. Sera from experimental animals and human volunteers immunized with a virus-like particle vaccine candidate exhibited B19 neutralizing titers equal to or greater than those observed in natural infections.Infection with human parvovirus B19 causes fifth disease, acute and chronic red cell aplasia, fetal hydrops, arthropathy, and other disorders. Antiviral antibodies limit B19 infection in vivo; however, the identification of serologic markers of protection has been hampered by the lack of a quantitative assay for parvovirus neutralization. A novel in vitro test for parvovirus neutralization has been developed using reverse transcriptase-polymerase chain reaction to detect viral transcripts in a B19-permissive cell line. Parvovirus neutralizing activity was measured in sera from naturally infected individuals, and common features of sera with high neutralizing capacity were identified as protection correlates. Sera that suppressed B19 replication in vitro demonstrated IgG reactivity with capsid proteins VP1 and VP2, but no linear relationship between antibody titer and neutralizing capacity was observed. Sera from experimental animals and human volunteers immunized with a virus-like particle vaccine candidate exhibited B19 neutralizing titers equal to or greater than those observed in natural infections.
Author Koenig, S
Bostic, J R
Brown, K E
Young, N S
Author_xml – sequence: 1
  givenname: J R
  surname: Bostic
  fullname: Bostic, J R
  email: bosticj@medimmune.com
  organization: MedImmune, Inc., Gaithersburg, MD 20878, USA. bosticj@medimmune.com
– sequence: 2
  givenname: K E
  surname: Brown
  fullname: Brown, K E
– sequence: 3
  givenname: N S
  surname: Young
  fullname: Young, N S
– sequence: 4
  givenname: S
  surname: Koenig
  fullname: Koenig, S
BackLink https://www.ncbi.nlm.nih.gov/pubmed/9952368$$D View this record in MEDLINE/PubMed
BookMark eNot0E1LxDAQBuAcFF2__oGQk7dqmrbZ9KjiFwgi6HmZbaZupE1qJimsv8Sfa8S9zAzDw3t4j9ie8w4ZOyvFZSm0uqrKWtV6jy2EkLIoddsesiOiTyFEXanlATto20ZWSi_Yz2sCF22EaGfk4GDYkiXue-4wxQCD_bbug9txTA55QJq8IyQePd-kERyfIMx-tiERvylbnuiPA3d-xiH7GQMhz0GOumCnCITF5IftiCGfvNuAdZlBF613xTr_DAci2J6w_R4GwtPdPmbv93dvt4_F88vD0-31c9HVehnzNO1S9bqWjVzLHpWpoFHGYFNXJWrQxhhAoYRaV7maMvNedUr3qupR1kYes4v_3Cn4r4QUV6OlDocBHPpEK9U2qtL1MsPzHUzrEc1qCnaEsF3tqpS_szd4tQ
CitedBy_id crossref_primary_10_1093_rheumatology_keaa230
crossref_primary_10_1016_j_jviromet_2007_06_017
crossref_primary_10_1089_088282404322875458
crossref_primary_10_1111_j_0041_1132_2004_04127_x
crossref_primary_10_1128_CMR_15_3_485_505_2002
crossref_primary_10_1002_jmv_21289
crossref_primary_10_1111_j_1537_2995_2005_04393_x
crossref_primary_10_3390_vaccines8010120
crossref_primary_10_1034_j_1399_3046_2001_00035_x
crossref_primary_10_1046_j_1537_2995_2001_41010130_x
crossref_primary_10_1089_088282401750234529
crossref_primary_10_1086_526523
crossref_primary_10_1016_S0369_8114_02_00303_6
crossref_primary_10_3390_vaccines9080860
crossref_primary_10_1006_viro_2002_1585
crossref_primary_10_1016_j_vaccine_2021_07_046
crossref_primary_10_1016_j_virol_2009_11_044
crossref_primary_10_1016_j_vaccine_2013_06_062
crossref_primary_10_1159_000053876
crossref_primary_10_1128_JVI_74_21_9903_9910_2000
crossref_primary_10_1016_j_virusres_2005_05_003
crossref_primary_10_1177_0961203310365715
crossref_primary_10_1016_S0166_0934_02_00195_7
crossref_primary_10_1016_S0264_410X_00_00258_9
crossref_primary_10_1002_jmv_10079
crossref_primary_10_1111_j_0004_8666_2002_00347_x
crossref_primary_10_1046_j_1423_0410_2003_00280_x
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1086/314648
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
Biology
ExternalDocumentID 9952368
Genre Journal Article
GroupedDBID ---
-DZ
-~X
..I
.2P
.55
.GJ
.I3
.XZ
.ZR
08P
0R~
123
1KJ
1TH
29K
2AX
2WC
36B
3O-
4.4
41~
48X
53G
5GY
5RE
5VS
5WD
6.Y
70D
85S
AABZA
AACGO
AACZT
AAHBH
AAHTB
AAJKP
AAJQQ
AAMVS
AANCE
AAOGV
AAPGJ
AAPNW
AAPQZ
AAPXW
AAQQT
AARHZ
AAUAY
AAUQX
AAVAP
AAWDT
AAWTL
AAYOK
ABBHK
ABDFA
ABDPE
ABEJV
ABEUO
ABGNP
ABIXL
ABJNI
ABKDP
ABLJU
ABNHQ
ABNKS
ABOCM
ABPEJ
ABPLY
ABPPZ
ABPTD
ABQLI
ABQNK
ABSAR
ABSMQ
ABTLG
ABVGC
ABWST
ABXSQ
ABXVV
ABZBJ
ACFRR
ACGFO
ACGFS
ACGOD
ACHIC
ACPQN
ACPRK
ACUFI
ACUTJ
ACUTO
ACYHN
ACZBC
ADBBV
ADEYI
ADGZP
ADHKW
ADHZD
ADIPN
ADJQC
ADOCK
ADQBN
ADRIX
ADRTK
ADULT
ADVEK
ADYVW
ADZXQ
AEGPL
AEGXH
AEJOX
AEKPW
AEKSI
AEMDU
AENEX
AENZO
AEPUE
AETBJ
AEUPB
AEWNT
AEXZC
AFFNX
AFFQV
AFFZL
AFHKK
AFIYH
AFOFC
AFQQW
AFSHK
AFXAL
AFXEN
AFYAG
AGINJ
AGKEF
AGKRT
AGMDO
AGQXC
AGSYK
AGUTN
AHMBA
AHMMS
AHXPO
AI.
AIAGR
AIJHB
AJEEA
ALMA_UNASSIGNED_HOLDINGS
ALUQC
APIBT
APJGH
APWMN
AQDSO
AQKUS
AQVQM
ATGXG
AXUDD
BAWUL
BAYMD
BCRHZ
BEYMZ
BHONS
BR6
BTRTY
BVRKM
BZKNY
C45
CDBKE
CGR
CS3
CUY
CVF
CZ4
D-I
DAKXR
DCCCD
DIK
DILTD
DOOOF
DU5
D~K
EBS
ECGQY
ECM
EE~
EIF
EIHJH
EJD
EMOBN
ENERS
ESX
F5P
F9B
FECEO
FLUFQ
FOEOM
FOTVD
FQBLK
GAUVT
GJXCC
GX1
H13
H5~
HAR
HQ3
HTVGU
HW0
HZ~
IH2
IOX
IPSME
J21
J5H
JAAYA
JBMMH
JENOY
JHFFW
JKQEH
JLS
JLXEF
JPM
JSG
JSODD
JST
KAQDR
KBUDW
KOP
KQ8
KSI
KSN
L7B
LSO
LU7
M49
MBLQV
MHKGH
MJL
ML0
MVM
N4W
N9A
NEJ
NGC
NOMLY
NOYVH
NPM
NU-
NVLIB
O0~
O9-
OAUYM
OAWHX
OCZFY
ODMLO
OJQWA
OJZSN
OK1
OPAEJ
OVD
OWPYF
O~Y
P0-
P2P
PAFKI
PEELM
PQQKQ
Q1.
Q5Y
QBD
RD5
ROX
ROZ
RUSNO
RW1
RXO
SA0
SJN
TCURE
TEORI
TJX
TMA
TR2
VH1
VXZ
W2D
W8F
WH7
X7H
X7M
Y6R
YAYTL
YIF
YKOAZ
YXANX
ZE2
ZGI
ZKG
ZXP
~91
7X8
ABPQP
ADNBA
ADQXQ
AEMQT
AJBYB
AJNCP
ALXQX
JXSIZ
ID FETCH-LOGICAL-c487t-c4d976f84252b2fe6d3a56dde5431e8a8dddae0606b308614d9f6c68f63fe24d2
IEDL.DBID 7X8
ISICitedReferencesCount 29
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000079566700011&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 0022-1899
IngestDate Thu Oct 02 07:02:28 EDT 2025
Wed Feb 19 01:19:15 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 3
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c487t-c4d976f84252b2fe6d3a56dde5431e8a8dddae0606b308614d9f6c68f63fe24d2
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 9952368
PQID 69563847
PQPubID 23479
ParticipantIDs proquest_miscellaneous_69563847
pubmed_primary_9952368
PublicationCentury 1900
PublicationDate 1999-03-01
PublicationDateYYYYMMDD 1999-03-01
PublicationDate_xml – month: 03
  year: 1999
  text: 1999-03-01
  day: 01
PublicationDecade 1990
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle The Journal of infectious diseases
PublicationTitleAlternate J Infect Dis
PublicationYear 1999
SSID ssj0004367
Score 1.7622808
Snippet Infection with human parvovirus B19 causes fifth disease, acute and chronic red cell aplasia, fetal hydrops, arthropathy, and other disorders. Antiviral...
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage 619
SubjectTerms Animals
Antibodies, Viral - blood
Antibody Formation
Capsid - immunology
Capsid Proteins
Cell Line
Erythema Infectiosum - immunology
Guinea Pigs
Humans
Immunoglobulin G - blood
Macaca mulatta
Mice
Mice, Inbred BALB C
Neutralization Tests
Parvoviridae Infections - immunology
Parvovirus B19, Human - immunology
Reference Values
Reverse Transcriptase Polymerase Chain Reaction - methods
Viral Vaccines
Title Quantitative analysis of neutralizing immune responses to human parvovirus B19 using a novel reverse transcriptase-polymerase chain reaction-based assay
URI https://www.ncbi.nlm.nih.gov/pubmed/9952368
https://www.proquest.com/docview/69563847
Volume 179
WOSCitedRecordID wos000079566700011&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1La9tAEB6Sugm99OEmJOlrDr0utb3yagWBkJaaHBrjQlt8MyvtbGIwkqOHwfkl-bmZ1QN8KTnkshethBiNZr7ZmfkG4CvFThpHWuhgbESg1VhEsXNCx5EhPaBA1lRK_36F06mez6PZHpx3vTC-rLKzibWhtlniz8i_KQbykk3pxfpO-JlRPrfaDtDYh55kIOMLusL5Dle4VGHHFT7ksGJnspBk-xDo_4PK2rlM3jzvtd7C6xZU4mWjBe9gj9I-HDRjJrd9OLxuE-jv4eF3ZdK6r4ytHJqWkQQzhylV9aHHPfsyXPquEcK8KaClAssM62l-uDb5Jtss86rA78MIfdn8DRpMsw2t0NNB5QVh6R1gbY7YR4p1ttr6oy--kNyaZcrbmm4K4V2oRYbvZnsEfyc___y4Eu1wBpFwjFPyahnJOJ_FG8UjR8pKM1ZsLH1zPWmjrbWGBhwfxZJFPuTtTiVKOyUdjQI7OoYXaZbSCWDiYhYi-8mYwYYLGbLaMLQ24KerIByrU_jSyX7Byu8zGialrCoWnfRP4bj5fIt1w9GxiCKOsJU-e_LWD_CqYWLwZWUfoef4r6dP8DLZlMsi_1yrFK_T2fUjWE3bxw
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Quantitative+analysis+of+neutralizing+immune+responses+to+human+parvovirus+B19+using+a+novel+reverse+transcriptase-polymerase+chain+reaction-based+assay&rft.jtitle=The+Journal+of+infectious+diseases&rft.au=Bostic%2C+J+R&rft.au=Brown%2C+K+E&rft.au=Young%2C+N+S&rft.au=Koenig%2C+S&rft.date=1999-03-01&rft.issn=0022-1899&rft.volume=179&rft.issue=3&rft.spage=619&rft_id=info:doi/10.1086%2F314648&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-1899&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-1899&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-1899&client=summon